(severe DILI concern) compound ketoconazole has an IC 50 of 4.6 µM and a C max of 11.3 µM. This results in a ratio (IC 50 /C max ) of 0.4, also named 'margin of safety' (MOS). Therefore, the in vitro system with hepatocyte spheroids predicts the in vivo situation for ketoconazole quite well. However, the situation is difficult for other compounds with severe DILI concern (category 1): ximelagatran shows an in vitro IC 50 of 150 µM, but the human plasma peak concentration (C max ) is only 0.45 µM. Therefore, the risk of human DILI has been massively underestimated by the in vitro system. Similar problems exist for the category 1 compounds dantrolene, methotrexate, stavudine and trovafloxacin (Proctor et al. 2017; Table S-3, S3h LiMT data). It is interesting to note that cytotoxicity allows a good prediction of human blood concentrations associated with an increased risk of DILI for some compounds, while it leads to a massive underestimation of other severe DILI compounds.
In recent years, much effort has been invested into the development of hepatocyte in vitro systems (Ehrhardt and Schmicke 2016; Ramboer et al. 2015; Verhulst et al. 2015; Hammad and Ahmed 2014; Hammad et al. 2017; Godoy et al. , 2015 Grinberg et al. 2014) . Besides cytotoxicity further readouts, such as gene expression or functional endpoints have been recommended (Grinberg et al. 2014; Reif et al. 2015; Rashidi et al. 2016; Arbo et al. 2016 ). However, a comprehensive study including a sufficiently large number of compounds for validation of these endpoints is not yet available. The merit of the present study (Proctor et al. 2017 ) is that it delivers a comprehensive cytotoxicity database, which clearly demonstrates that cytotoxicity alone is not sufficient to predict human DILI. In conclusion, the hunt for an accurate in vitro system quantitatively predicting human hepatotoxicity has only just begun. 
